- Home
- CMAX vs BGLC Comparison
CMAX vs BGLC Comparison
Compare CMAX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- BGLC
- Stock Information
- Founded
- CMAX 2011
- BGLC 2017
- Country
- CMAX United States
- BGLC Malaysia
- Employees
- CMAX N/A
- BGLC N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- BGLC Medical Specialities
- Sector
- CMAX Technology
- BGLC Health Care
- Exchange
- CMAX Nasdaq
- BGLC Nasdaq
- Market Cap
- CMAX 7.2M
- BGLC 7.6M
- IPO Year
- CMAX N/A
- BGLC N/A
- Fundamental
- Price
- CMAX $1.69
- BGLC $0.30
- Analyst Decision
- CMAX Hold
- BGLC
- Analyst Count
- CMAX 1
- BGLC 0
- Target Price
- CMAX $6.40
- BGLC N/A
- AVG Volume (30 Days)
- CMAX 787.8K
- BGLC 78.7K
- Earning Date
- CMAX 11-26-2024
- BGLC 11-20-2024
- Dividend Yield
- CMAX N/A
- BGLC N/A
- EPS Growth
- CMAX N/A
- BGLC N/A
- EPS
- CMAX N/A
- BGLC N/A
- Revenue
- CMAX $784,551,000.00
- BGLC $9,183,168.00
- Revenue This Year
- CMAX $13.01
- BGLC N/A
- Revenue Next Year
- CMAX $32.42
- BGLC N/A
- P/E Ratio
- CMAX N/A
- BGLC N/A
- Revenue Growth
- CMAX 9.06
- BGLC N/A
- 52 Week Low
- CMAX $1.18
- BGLC $0.28
- 52 Week High
- CMAX $30.00
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- CMAX 43.35
- BGLC 24.52
- Support Level
- CMAX $1.63
- BGLC $0.32
- Resistance Level
- CMAX $1.81
- BGLC $0.38
- Average True Range (ATR)
- CMAX 0.31
- BGLC 0.02
- MACD
- CMAX -0.02
- BGLC -0.00
- Stochastic Oscillator
- CMAX 21.93
- BGLC 18.27
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.